SLC6A1 and depressive disorder: Broad studieson inhibition of the transporters, especially GAT1, resulted in thedevelopment of tiagabine (GAT1 inhibitor) which has been the onlyregistered drug targeting GABA transport so far.8−10 This anticonvulsantdrug is not devoid of substantial adverse reactions, such as asthenia,dizziness, nervousness, and depression.8 Therefore, the search for antiepileptic agents also includes otherGABA transporters as therapeutic targets.